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Abstract
Background: An unclassified variant (UV) in exon 1 of the MLH1 gene, c.112A > C, p.Asn38His, was found in six
families who meet diagnostic criteria for Lynch syndrome. The pathogenicity of this variant was unknown. We aim
to elucidate the pathogenicity of this MLH1 variant in order to counsel these families adequately and to enable
predictive testing in healthy at-risk relatives.
Methods: We studied clinical data, microsatellite instability and immunohistochemical staining of MMR proteins,
and performed genealogy, haplotype analysis and DNA testing of control samples.
Results: The UV showed co-segregation with the disease in all families. All investigated tumors showed a
microsatellite instable pattern. Immunohistochemical data were variable among tested tumors. Three families had a
common ancestor and all families originated from the same geographical area in The Netherlands. Haplotype
analysis showed a common haplotype in all six families.
Conclusions: We conclude that the MLH1 variant is a pathogenic mutation and genealogy and haplotype analysis
results strongly suggest that it is a Dutch founder mutation. Our findings imply that predictive testing can be
offered to healthy family members. The immunohistochemical data of MMR protein expression show that
interpreting these results in case of a missense mutation should be done with caution.
Background
About 3% of all colorectal cancers is due to Lynch syn-
drome, an autosomal dominant condition caused by
germline mutations in one of the DNA mismatch repair
(MMR) genes, MLH1, MSH2, MSH6 and PMS2 [1]. Car-
riers of a mutation in one of these MMR genes have a
high risk of developing colorectal cancer, endometrial
cancer and also an increased risk of specific other malig-
nancies including ovarian, upper urinary tract, gastric,
small intestinal and biliary tract cancer and adenoma or
carcinoma of the sebaceous gland [1].
In families who meet the Amsterdam and/or the
revised Bethesda criteria [2], tumor examination is
indicated including an assay for microsatellite instability
(MSI) and immunohistochemistry (IHC) for mismatch
repair (MMR) protein expression [2]. When a tumor
shows MSI, with or without alterations in immunohisto-
chemical staining of these proteins, mutation analysis of
the MLH1, MSH2, MSH6 and PMS2 genes is offered.
Missense mutations comprise about 20% of all patho-
genic mutations associated with Lynch syndrome [3,4].
For most missense mutations, convincing evidence for
pathogenicity is lacking, and these are called unclassified
variants (UVs) or variants of uncertain clinical signifi-
cance [3,5,6]. To gain more insight in the nature of such
an UV, it is useful to study clinical, morphological and
molecular features of affected patients and their families.
In this study, we describe six Dutch families with
Lynch syndrome and a previously described UV in the
MLH1 gene [7-10]. We have combined data from
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families like co-segregation of the MSI/IHC results and
the UV with disease, germline mutation analysis of
MMR genes, haplotype analysis, geneaology, and germ-
line mutation testing of healthy controls to gain more
insight into the clinical significance of this UV.
Methods
Patients and families
Probands of these six families were referred to a Family
Cancer Clinic for genetic counselling because of a per-
sonal and/or family history of cancer. A detailed pedi-
gree analysis was performed and, if possible, medical
data of affected relatives were verified (Figure 1, Figure
2, Figure 3, Figure 4, Figure 5, Figure 6). For all affected
relatives clinical data were recorded including sex, type
of cancer, age at diagnosis or at death.
Microsatellite instability analysis and
immunohistochemistry for MMR proteins
For MSI analysis, genomic DNA was isolated from for-
malin-fixed and paraffin-embedded tumor and normal
tissue using standard procedures [11-13]. At least five
markers from the Bethesda panel with some additional
markers were used to assess MSI. According to interna-
tional guidelines, a tumor was considered having a MSI-
high phenotype when at least two out of five markers
were instable [12].
IHC was performed on formalin-fixed, paraffin-
embedded tumor and normal tissues. Slides were stained
following routine diagnostic procedures [13] using
appropriate antibodies against MLH1, MSH2, MSH6
and, when available, PMS2 proteins.
The cancer specimens were acquired from different hos-
pitals where the patients were treated. These pathology
departments used a variety of protocols for formalin-fixa-
tion and paraffin-embedding. MSI and IHC were con-
ducted on 18 different specimens of 13 patients, including
13 colorectal tumors (two of which only IHC and no
MSI), 1 sebaceous gland carcinoma, 1 sebaceous gland
adenoma (only MSI, no IHC), 1 endometrial carcinoma, 1
duodenal carcinoma and 1 metastasis presumably of a pri-
mary tumor of the gastrointestinal tract or pancreas.
Mutation analysis
When a tumor was classified as MSI high, with or with-
out alterations in immunohistochemical staining of one
or more of the MMR proteins, germline mutation analy-
sis was offered. DNA was isolated from peripheral blood
lymphocytes of affected patients.
For some patients, a complete germline mutation ana-
lysis for not only MLH1 [GenBank: NM_000249] but
also MSH2 [GenBank: NM_000251] and MSH6 [Gen-
Bank: NM_000179], and in some cases PMS2 [GenBank:
NM_000535], was performed (see Additional file 1 -
Table S1: Microsatellite instability- and immunohisto-
chemistry results in patients with MLH1 missense
mutation).
Genealogy
Extended pedigrees of 6 generations were studied to
investigate possible common ancestry of the six families.
Shared haplotype analysis
Haplotype analysis was performed of all probands and
affected relatives if available to investigate a possible
Figure 1 Pedigree from Family 1 (VUmc C198). Co = colon cancer. Lu = lung cancer. Es = oesophageal cancer. Pr = prostate cancer. Ur =
ureteral cell cancer. Sa = sarcoma.
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VNTR markers, with 3 markers flanking each side of
the gene.
Control population
Germline mutation analysis for this UV was performed
by DNA sequencing in 94 healthy, anonymous Dutch
controls.
Results
Clinical phenotype of families
All six families fulfilled the revised Bethesda criteria,
while Families 1, 2 and 4 also fulfilled the Amsterdam II
criteria. Figure 1, Figure 2, Figure 3, Figure 4, Figure 5
and Figure 6 show phenotypic details of these families.
Family 1 has features of Muir-Torre syndrome, a phe-
notypic variant of Lynch syndrome [14].
MSI and IHC
All tested colorectal and other carcinomas showed a
MSI-high phenotype. Of 17 tumors that were examined
immunohistochemically for MMR protein expression, 6
stained negative for one or more MMR proteins. Only
one of these was negative for MLH1.M S Ia n dI H C
results are summarized in Table S1 (see Additional file
1 - Table S1: Microsatellite instability- and immunohis-
tochemistry results in patients with MLH1 missense
mutation).
Germline mutation analysis
In 13 affected patients an UV in exon 1 of the MLH1
gene, c.112A > C, p.Asn38His, was found. All tested
affected patients carried the UV, indicating complete co-
segregation of the UV with the disease. In some patients
additional germline mutation analysis of the MSH2,
Figure 2 Pedigree from Family 2 (UMCU1). Co = colon cancer. Ut = endometrial cancer. Po = colonic polyp. Br = breast cancer. Cx = cervical
cancer. # ‘cancer of bones’ according to family; no review of pathology. ## ‘cancer of bones’ according to family; consistent with neuroblastoma
according to pathology report.
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Additional file 1 - Table S1: Microsatellite instability-
and immunohistochemistry results in patients with
MLH1 missense mutation) and no mutations were
found in these genes.
Genealogy
All ancestors of the six families originated from the
same region (Mid-East Netherlands) and certain family
names were frequently found in the different pedigrees.
Three families (Families 1, 2 and 6) were shown to have
a common ancestor, who linked the independently
referred individuals of these families together into a
seven-generation family (Figure 7).
Haplotype analysis
All tested patients (n = 12) from six families were
shown to share a common allele (see Additional file 2 -
Table S2: Haplotype analysis results).
Controls
The MLH1 variant c.112A > C was not detected in
DNA of 94 healthy anonymous controls.
Discussion
In this study, we show that the MLH1 alteration, c.112A
> C (p.Asn38His), most likely represents a pathogenic
missense mutation causing Lynch syndrome.
Criteria for pathogenicity of missense mutations
include difference in the chemical properties of the
amino acid (Grantham score), evolutionary conservation
of the amino acid, absence in the normal population,
co-segregation with the disease and association between
MSI and/or absence of immunohistochemical staining
for the MMR protein in the tumor [4]. From literature
and available databases, it is known that this mutation
lies in a functional domain of the MLH1 gene and the
Asn-38 codon has a full evolutionary conservation in
the MLH1 protein [3,8,15]. Furthermore, another mis-
s e n s em u t a t i o ni nt h i sc o d o n ,p . A s n 3 8 A s p ,c . 1 1 2 A>G ,
is proven to be pathogenic and affects the activity of the
MLH1 protein: the protein cannot bind Mg++, does not
have ATPase activity and cannot correct for a MLH1
deficiency [15]. Lack of mismatch repair activity has also
been described recently for this p.Asn38Asp mutation
[10]. The variant described in our study induces a
greater shift in Grantham score than the variant
described by Takahashi [15]. Also, according to SIFT
and MAPP-MMR scores this UV should be considered
pathogenic [9,10].
The results of our study show a complete co-segrega-
tion between the cancer cases (colorectal, endometrial
and other Lynch syndrome related cancers) and the
mutation in six families. All tumors show an MSI high
phenotype, mostly without alterations in immunohisto-
chemical protein expression. Pathogenic mutations are
Figure 3 Pedigree from Family 3 (UMCU2). Co = colon cancer. Pa = pancreatic cancer. Po = colonic polyp. # malignant histiocytoma as
stated in a letter from 1974; no specification was given, pathology could not be reviewed.
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chemical staining of one or more MMR proteins. In
general, immunohistochemical staining is considered to
be more sensitive in detecting MMR gene mutations
than MSI analysis [16-18]. However, missense mutations
can have subtle effects on the protein products of the
MMR genes, which can result in loss of function while
maintaining intact protein that is able to bind antibodies
[19]. Therefore, immunochemistry can show normal
staining of the proteins, as seen in the majority of the
tumors in this study. In accordance to our findings,
other studies have also described tumors showing
an MSI high phenotype but normal expression of
the MMR proteins [7,10]. We also observed loss of
immunostaining of PMS2 in some tumors. Loss of
PMS2 protein expression is often seen in tumors from
MLH1 mutation carriers, since PMS2 and MLH1 form
heterodimeric complexes in mismatch repair [19]. Sur-
prisingly, we also observed loss of MSH2 and/or MSH6
protein expression. An artefact in the methods used in
this study is unlikely since staining in normal tissue of
the same patients was normal and others also have
reported loss of MSH2 and MSH6 protein expression in
at u m o ro faMLH1 missense mutation carrier [19] and
control tissue showed normal staining. Immunostaining
can be dependent on a second hit which can differ for
each tumor [20].
Taken together, in the caseo fm i s s e n s em u t a t i o n s ,
which might lead to presence of abnormal protein pro-
ducts that still have binding capacity for antibodies, MSI
might be more sensitive for detecting patients with
MMR gene mutations than immunohistochemical stain-
ing [21,22].
All tested family members share a common allele and
their ancestors originate from the same region in The
Netherlands. Genealogical studies showed that three
families have a common ancestor. The variant in our
families is reported earlier by Van Puijenbroek [7], who
studied genome-wide copy neutral loss of heterozygosity
(LOH) in a cohort of Dutch familial and sporadic color-
ectal carcinomas. To our knowledge, this mutation has
not been reported in families outside The Netherlands
[3,10,23,24]. Together with the genealogy and haplotype
analysis, this makes the mutation likely to be a Dutch
founder mutation.
In the described families, a Lynch syndrome pheno-
type is clearly present. In addition to colorectal and
endometrial cancer, other cancers were also present in
mutation carriers: skin cancers (sebaceous gland carci-
noma and squamous cell carcinoma), sarcoma, malig-
nant histiocytoma, ureteral cell cancer, astrocytoma and
bone tumors not otherwise specified. Most of these can-
cers fit within the tumor spectrum of Lynch syndrome.
However, sarcoma and histiocytoma are not common
tumor types seen in Lynch syndrome. There are some
studies that suggest these tumors can be part of the
tumor spectrum and a causal relationship with MSH2
has been shown [25-27]. In our study, we confirmed
that the patient with the sarcoma is a carrier of the
MLH1 mutation. We were not able to confirm that the
patient affected with histiocytoma has been a carrier of
the MLH1 gene mutation. In Family 1 (VUmc C198),
the family history is consistent with Muir-Torre syn-
drome [14]. Sebaceous gland carcinomas are part of the
Lynch syndrome tumor spectrum [28,29]. Our patients
affected with sebaceous gland carcinoma and sebaceous
gland adenoma were proven to be carriers of the MLH1
gene mutation and tumor specimens showed a MSI-high
Figure 4 Pedigree from Family 4 (NKI F1390). Co = colon cancer.
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Page 5 of 9Figure 5 Pedigree from Family 5 (UMCG1). Co = colon cancer. Ut = endometrial cancer. Pa = pancreatic cancer.
Figure 6 Pedigree from Family 6 (UMCG2). St = gastric cancer. Pa = pancreatic cancer. Lu = lung cancer. Co = colon cancer. ca = carcinoma.
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Torre syndrome.
Conclusions
The results of our study show compelling evidence that
the described missense mutation c.112A > C, p.Asn38-
His, affecting a strongly conserved position in the ATP-
ase domain of the MLH1 gene, is indeed a pathogenic
germline alteration which causes Lynch syndrome.
Therefore, predictive testing can be offered to non-
affected family members. In addition, the results of IHC
are not unambiguous and apparently not reliable in
diagnosing Lynch syndrome in at least a part of the
families with missense mutations in MMR genes.
Additional material
Additional file 1: Table S1. Microsatellite instability- and
immunohistochemistry results in patients with MLH1 missense mutation
and affected family members.
Additional file 2: Table S2. Haplotype analysis results.
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